Esmonova-DSR Capsule contains a combination of Domperidone 30mg and Esomeprazole 40mg, formulated to provide effective management of gastrointestinal disorders characterized by acid reflux, heartburn, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The combined action of these agents offers both symptomatic relief and promotes healing of the esophageal mucosa. Esmonova-DSR is indicated for patients suffering from GERD with associated motility disorders, functional dyspepsia, and other acid-peptic diseases where enhanced gastric emptying and acid suppression are required. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, prolonged QT interval, and concurrent use of medications that may interact adversely. Common side effects may include headache, dry mouth, and abdominal discomfort. Patient adherence to prescribed dosage and duration is essential for optimal therapeutic outcomes.